Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price Volatility

Simply Wall St

Mon, February 16, 2026 at 12:11 AM GMT+9 3 min read

In this article:

MDGL

-1.92%

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.

Madrigal Pharmaceuticals (MDGL) has drawn investor attention after recent share price moves, with the stock showing a 1 day return of 1.92% and a 7 day return of 2.70% heading into this week.

See our latest analysis for Madrigal Pharmaceuticals.

That shorter term weakness, with a 30 day share price return of 7.37% decline and a year to date share price return of 21.75% decline from US$464.71, sits alongside a much stronger long term picture. The 5 year total shareholder return of 281.28% suggests earlier optimism around Madrigal Pharmaceuticals has not fully carried through in recent months as investors reassess growth potential and risk around its MASH focused pipeline.

If this kind of volatility has your attention, it could be a good moment to broaden your watchlist and scan our screener of 25 healthcare AI stocks for more ideas in cutting edge healthcare.

With Madrigal showing a 21.75% year-to-date decline alongside a 5-year total return above 280%, investors now face a key question: is the current price a discount on future MASH growth, or is that already fully reflected?

Most Popular Narrative: 23% Undervalued

With Madrigal Pharmaceuticals last closing at $464.71 against a narrative fair value estimate of about $603.47, the current share price sits well below that modelled view and puts the focus squarely on what is being assumed for Rezdiffra and MASH over the next decade.

The rapid uptake and long term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top line growth and supports margin expansion due to extended pricing power.

Read the complete narrative.

Curious what revenue path and margin profile sit behind that fair value gap? The narrative leans on aggressive top line expansion, a sharp earnings swing, and a much richer future earnings multiple tied to MASH leadership assumptions.

Result: Fair Value of $603.47 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this hinges on a single drug story, where tougher GLP 1 competition or weaker than expected F4 and cirrhosis adoption could quickly challenge that upside.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Build Your Own Madrigal Pharmaceuticals Narrative

If you look at this and think the assumptions do not quite fit your view, you can stress test the data yourself and build a version that reflects your own research, then Do it your way in just a few minutes.

Story Continues  

A great starting point for your Madrigal Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Do not stop with a single stock story when you can line up a full bench of ideas that fit your goals and risk comfort in minutes.

Target potential value opportunities by scanning companies on our screener of 53 high quality undervalued stocks that combine quality fundamentals with prices that may sit below their fair value estimates.

Prioritise resilience by checking out our collection of 84 resilient stocks with low risk scores if you want businesses with fewer warning signs and steadier risk profiles.

Get ahead of the crowd by browsing our screener containing 23 high quality undiscovered gems where strong fundamentals have not yet attracted widespread attention from the market.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include MDGL.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info